Carriage of Ser217Leu and Ala541Thr Variants of ELAC2 Gene and Risk Factors in Patients with Prostate Cancer in Burkina Faso

Table 5

Association between ELAC2 gene genotypes and prostate cancer.

Genotypes		Controls	Cases		PCaWFH vs. controls		PCaFH vs. controls		Cases vs. controls
Ser217Leu	Ala541Thr		CPS (%)	CPH (%)	OR (95% IC)		OR (95% IC)		OR (95% IC)
CC		20 (52.63)	12 (66.67)	6 (42.86)	Reference
CT		16 (42.11)	5 (27.78)	7 (50.00)	0.52 (0.15–1.79)	0.374	1.46 (0.41–5.21)	0.747	0.89 (0.35–2.27)	1.000
TT		2 (5.26)	1 (5.55)	1 (7.14)	0.83 (0.06–0.20)	1.000	1.67 (0.13–21.73)	1.000	0.95 (0.12–7.42)	1.000
CT/TT		18 (47.37)	6 (33.33)	8 (57.14)	0.55 (0.17–1.79)	0.393	1.48 (0.43–5.09)	0.755	0.90 (0.36–2.21)	1.000
	GG	32 (84.21)	14 (77.78)	7 (57.14)	Reference
	GA	6 (15.79)	4 (22.22)	6 (42.86)	1.52 (0.37–6.26)	0.710	4.57 (1.13–18.47)	0.050	1.90 (0.61–5.90)	0.393
	AA	0 (0.00)	0 (0.00)	0 (0.00)	NA	NA	NA	NA	NA	NA
	GA/AA	6 (15.79)	1 (8.33)	2 (25.00)	1.52 (0.37–6.26)	0.710	4.57 (1.13–18.47)	0.050	1.90 (0.61–5.90)	0.393
CC	GG	19 (50.00)	11 (61.11)	6 (46.15)	Reference
CT/TT	GG	13 (34.21)	3 (16.67)	3 (23.08)	0.39 (0.09–1.71)	0.322	0.73 (0.15–3.46)	1.000	0.58 (0.19–1.72)	0.425
CC	GA/AA	1 (2.63)	1 (5.55)	0 (0.00)	1.72 (0.09–0.15)	1.000	NA	NA	0.95 (0.05-16-26)	1.000
CT/TT	GA/AA	5 (13.16)	3 (16.67)	4 (30.77)	1.04 (0.21–5.19)	1.000	2.53 (0.51–12.59)	0.395	1.71 (0.48–6.03)	0.533

NA: not applicable, PCaFH: prostate cancer with family history, and PCaWFH: prostate cancer without family history.